

CORRIGENDUM

A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

L. A. Dunn, M. G. Fury, H. Xiao, S. S. Baxi, E. J. Sherman, S. Korte, C. Pfister, S. Haque, N. Katabi, A. L. Ho & D. G. Pfister

Ann Oncol 2017; 28: 2533–2538 (doi: 10.1093/annonc/mdx346)

In the original article, the funding information contained the wrong grant number: CA008747, rather than CA008748. This has now been corrected.